Spyre Therapeutics Inc. experienced a notable rise in its stock price following the announcement of a significant public offering.
Spyre Therapeutics Inc. (NASDAQ:SYRE) saw its stock surge by 7.25% yesterday, closing at CA$85.69. This positive movement was primarily driven by the company’s announcement regarding a public offering aimed at advancing its clinical pipeline.
Investor takeaway: The successful pricing of the public offering indicates investor confidence in Spyre's future growth prospects, particularly in its clinical programs across various therapeutic areas.
Advertisement
Spyre Therapeutics Inc.
SYRE.US
SYRE.US
Spyre Therapeutics Inc.
WealthAwesomeMarket cap
$8.01B
52W high
$110.17
52W low
$18.71
1W change
-8.05%
Beta
3.11
Analyst Price Targets
Based on 17 analysts covering SYRE · as of Oct 5, 2026
Wall Street analysts forecast SYRE stock price to rise 40.3% over the next 12 months.
Consensus
Strong Buy4.82 / 5.00
Avg. Target
C$120.21
+40.3% Upside
Current Price
C$85.69
Last close
Analyst Breakdown (17 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on SYRE's historical volatility
30-Day Vol
58.3%
Annualized
90-Day Vol
66.5%
Annualized
Trend (90d)
-39.4%
Annualized drift
90d Mean
C$74.44
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$81.76 | C$66.87 – C$99.97 |
| 60 trading days | C$78.02 | C$58.70 – C$103.68 |
| 90 trading days | C$74.44 | C$52.55 – C$105.46 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
$350 million
Spyre Therapeutics announced a public offering expected to generate approximately $350 million to support its clinical pipeline.
Bull case
The $350 million public offering at $85 per share strengthens Spyre's financial position. This funding will help the company conduct critical clinical trials and development initiatives, potentially leading to significant advancements in its product pipeline.
Bear case
Despite the positive stock movement, potential investors should consider the risks associated with clinical trials and the competitive landscape in the biopharmaceutical industry, which could impact Spyre's future performance.
Public Offering Details
Advertisement
Spyre Therapeutics announced the pricing of its underwritten public offering of 4.12 million shares at a price of $85 per share. The offering is expected to close on or about October 7, 2026, and includes an option for underwriters to purchase additional shares worth up to $52.5 million. The gross proceeds from this offering are anticipated to be approximately $350 million.
Use of Proceeds
The funds raised from the public offering will be directed towards advancing Spyre's clinical pipeline, particularly in Gastroenterology, Rheumatology, and Dermatology. This includes funding for preclinical work, clinical trials, and the readiness for Phase 3 studies, as well as supporting the late-stage development of SPY072 for hidradenitis suppurativa.
Market Reaction
Following the announcement of the public offering, Spyre's stock price saw a significant uptick, reflecting positive investor sentiment. The increase in stock price shows confidence in the company's strategic direction and its potential to deliver on clinical advancements.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
